Clinical research
AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.
The findings from the late-stage trial of Vyrologix have not been published, but CytoDyn said it is preparing a manuscript of the study data for submission.
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
It was another busy week for clinical trial announcements. Here’s a look.
Apellis Pharmaceuticals terminated its investigational COVID-19 asset after study data showed the therapeutic failed to reduce mortality rate in patients compared to standard of care.
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
Gastrointestinal and autoimmune company Arena Pharmaceuticals announced mixed topline results for the Phase IIb trial of its oral cannabinoid receptor type 2 (CB2) agonist olorinab.
The topline data from the BRAVE-AA2 study in 546 adults showed both 2 mg and 4 mg doses of Olumiant regrew hair in adult patients with more than 50% scalp hair loss, compared with placebo.
The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that “there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.”
STI-2099 is a formulation of its antibody against COVID-19 that can be taken in a nasal spray. It is also evaluating the antibody in an intravenous form (STI-2020) in a Phase I trial.
PRESS RELEASES